dChan
Anonymous ID: aba81e July 29, 2020, 11:12 p.m. No.10122469   🗄️.is 🔗kun   >>2580

Hydrazine sulfate in cancer patients with weight loss. A placebo-controlled clinical experience

 

https://pubmed.ncbi.nlm.nih.gov/3791153/

 

Abstract

Hydrazine sulfate was evaluated using 24-hour dietary recalls and body weight determinations before and after 30 days of either placebo or hydrazine (60 mg, 3 times/d) oral administration in 101 heavily pretreated cancer patients with weight loss. After 1 month, 83% of hydrazine and only 53% of placebo patients completing repeat evaluation maintained or increased their weight (P less than 0.05). In addition, appetite improvement was more frequent in the hydrazine group (63% versus 25%, P less than 0.05). Although caloric intake was only slightly greater in hydrazine-treated patients, an increased caloric intake was more commonly associated with weight gain in patients receiving hydrazine compared with those receiving placebo (81% versus 53%, respectively). Hydrazine toxicity was mild, with 71% of patients reporting no toxic effects. Hydrazine sulfate circulatory levels were obtained from a subset of 14 patients who completed 30 days of treatment, with a single sample obtained in the morning at least 9 hours after the last dose. Mean maintenance hydrazine sulfate levels, determined using a spectrofluorometric assay, ranged from 0 to 89 ng/ml (mean 45 +/- 16 ng/ml). These data, which demonstrate an association between 1 month of hydrazine sulfate administration and body weight maintenance in patients with cancer, suggest future clinical trials of hydrazine sulfate are indicated to definitively assess its long-term impact on important clinical outcome parameters in defined cancer populations.

Anonymous ID: aba81e July 29, 2020, 11:27 p.m. No.10122568   🗄️.is 🔗kun   >>2583

MSM media loves to practice medicine without a licence and dcare the viewers into thinking that HCQ causes heart attacks. That is NOT what the doctors say

Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection

 

https://www.ahajournals.org/doi/10.1161/CIRCEP.120.008662

 

Background:

The novel SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is responsible for the global coronavirus disease 2019 pandemic. Small studies have shown a potential benefit of chloroquine/hydroxychloroquine±azithromycin for the treatment of coronavirus disease 2019. Use of these medications alone, or in combination, can lead to a prolongation of the QT interval, possibly increasing the risk of Torsade de pointes and sudden cardiac death.

 

Methods:

Hospitalized patients treated with chloroquine/hydroxychloroquine±azithromycin from March 1 to the 23 at 3 hospitals within the Northwell Health system were included in this prospective, observational study. Serial assessments of the QT interval were performed. The primary outcome was QT prolongation resulting in Torsade de pointes. Secondary outcomes included QT prolongation, the need to prematurely discontinue any of the medications due to QT prolongation, and arrhythmogenic death.

 

Results:

Two hundred one patients were treated for coronavirus disease 2019 with chloroquine/hydroxychloroquine. Ten patients (5.0%) received chloroquine, 191 (95.0%) received hydroxychloroquine, and 119 (59.2%) also received azithromycin. The primary outcome of torsade de pointes was not observed in the entire population. Baseline corrected QT interval intervals did not differ between patients treated with chloroquine/hydroxychloroquine (monotherapy group) versus those treated with combination group (chloroquine/hydroxychloroquine and azithromycin; 440.6±24.9 versus 439.9±24.7 ms, P=0.834). The maximum corrected QT interval during treatment was significantly longer in the combination group versus the monotherapy group (470.4±45.0 ms versus 453.3±37.0 ms, P=0.004). Seven patients (3.5%) required discontinuation of these medications due to corrected QT interval prolongation. No arrhythmogenic deaths were reported.

 

Conclusions:

In the largest reported cohort of coronavirus disease 2019 patients to date treated with chloroquine/hydroxychloroquine±azithromycin, no instances of Torsade de pointes, or arrhythmogenic death were reported. Although use of these medications resulted in QT prolongation, clinicians seldomly needed to discontinue therapy. Further study of the need for QT interval monitoring is needed before final recommendations can be made.

Anonymous ID: aba81e July 29, 2020, 11:28 p.m. No.10122583   🗄️.is 🔗kun

>>10122568

QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin

 

https://pubmed.ncbi.nlm.nih.gov/32654098/

 

Abstract

Purpose: Hydroxychloroquine, chloroquine, and azithromycin have been used for treatment of COVID-19, but may cause QT prolongation. Minority populations are disproportionately impacted by COVID-19. This study evaluates the risk of QT prolongation and subsequent outcomes after administration of these medications in largely underrepresented minority COVID-19 patients.

 

Methods: We conducted an observational study on hospitalized COVID-19 patients in the Montefiore Health System (Bronx, NY). We examined electrocardiograms (ECG) pre/post-medication initiation to evaluate QTc, HR, QRS duration, and presence of other arrhythmias.

 

Results: One hundred five patients (mean age 67 years; 44.8% F) were analyzed. The median time from the first dose of any treatment to post-medication ECG was 2 days (IQR: 1-3). QTc in men increased from baseline (440 vs 455 ms, p < 0.001), as well as in women (438 vs 463 ms, p < 0.001). The proportion of patients with QT prolongation increased significantly (14.3% vs 34.3%, p < 0.001) even when adjusted for electrolyte abnormalities. The number of patients whose QTc 500 ms was significantly increased after treatment (16.2% vs. 4.8%, p < 0.01). Patients with either QTc > 500 ms or an increase of 60 ms had a higher frequency of death (47.6% vs. 22.6%, p = 0.02) with an odds ratio of 3.1 (95% CI: 1.1-8.7). Adjusting for race/ethnicity yielded no significant associations.

 

Conclusions: Hydroxychloroquine, chloroquine, and/or azithromycin were associated with QTc prolongation but did not result in fatal arrhythmias. Our findings suggest that any harm is unlikely to outweigh potential benefits of treatment. Careful risk-benefit analyses for individual patients should guide the use of these medications. Randomized control trials are necessary to evaluate their efficacies.

Anonymous ID: aba81e July 29, 2020, 11:36 p.m. No.10122634   🗄️.is 🔗kun   >>2671 >>2679 >>2733

Russia WILL NOT ban hydroxychloroquine, drug taken by US President Trump, for use in treating Covid-19

 

https://www.rt.com/russia/490018-russia-not-ban-drug-covid19/

 

Russia’s Health Ministry announced it will not ban hydroxychloroquine, seen by some as potentially dangerous. The drug, touted by US President Trump, has been suspended for use in treating Covid-19 in France, Italy, and Belgium.

On Thursday, the Russian Health Ministry stated on its website that hydroxychloroquine’s effectiveness and safety in the treatment of coronavirus is continually being monitored, but the ministry is not taking any steps towards outlawing it. This decision is in sharp contrast to moves made by some European countries which, due to safety concerns, have completely stopped the prescription of the drug to fight the coronavirus.

 

Look at how COVID fatalities in Russia were rising sharply and then suddenly hit a plateau

Anonymous ID: aba81e July 29, 2020, 11:51 p.m. No.10122739   🗄️.is 🔗kun

>>10122661

 

All I did was take the original PDF, and run it through some light PDF compression to get it small enough to post here.

 

When the bread is archived, the only attachments which continue to work, are those which are also posted in a more recent bread. In other words, most attachments disappear when the breads are archived.

 

Not sure about GermanAnon's archive on Mega.nz